The study was led by Youquan Gu of The First Affiliated Hospital of Lanzhou University in China, together with colleagues from Lanzhou University and Gansu Provincial Hospital. The team enrolled 234 patients treated for acute ischemic stroke, the most common form of stroke, caused by a blockage of blood flow to part of the brain. All laboratory values were drawn at admission, before any treatment began. The researchers then tracked two outcomes: the initial severity of the stroke, measured with the National Institutes of Health Stroke Scale, and the functional status of patients at discharge, measured with the modified Rankin Scale.

Bilirubin is a yellow pigment produced when the body breaks down heme, the iron-containing molecule at the core of hemoglobin. It has long been viewed mainly as a liver-related value, but in recent years scientists have recognized that it also acts as a powerful antioxidant, neutralizing reactive molecules that damage tissue. Direct bilirubin is the form that has been processed by the liver and released into the blood. Because stroke triggers an intense inflammatory response that generates reactive oxygen species, researchers have suspected that bilirubin might be consumed in the process, making blood levels a potential window into the intensity of the inflammatory storm.

The results were striking. Patients with higher direct bilirubin levels at admission had significantly more severe strokes, and direct bilirubin was an independent predictor of stroke severity even after accounting for other clinical factors. The derived ratio, DBLR, performed even better. Patients with higher DBLR values had both more severe strokes and worse functional outcomes at discharge. In statistical models, DBLR was an independent predictor of both outcomes, suggesting that the ratio captures something that direct bilirubin alone does not.

The mechanism behind the ratio may lie in the two values that make it up. Lymphocytes are white blood cells that help coordinate the immune response, and their numbers typically drop during acute inflammatory events, a phenomenon clinicians call lymphopenia. Because severe strokes trigger a more intense inflammatory response, they cause a greater drop in lymphocyte counts. Dividing direct bilirubin by the lymphocyte count therefore produces a value that rises when the inflammatory storm is intense, combining a marker of antioxidant consumption with a marker of immune suppression in a single number.

The clinical implications are significant. Because both direct bilirubin and lymphocyte counts are measured routinely in every hospital laboratory, DBLR could be calculated within minutes of a patient’s arrival, without any additional cost or delay. The researchers suggest that the ratio could eventually help clinicians identify patients at high risk of severe disability, guiding decisions about treatment intensity and rehabilitation planning. The value could also serve as a rapid and objective way to track the intensity of the inflammatory response during the hospital stay.

The study has limitations. It was conducted at a single center in China, and the findings will need to be replicated in larger and more diverse populations. The researchers also note that the ratio was associated with outcomes during the hospital stay, but the study did not track patients after discharge, so the long-term implications remain unknown. In addition, because bilirubin levels can be affected by liver disease and other conditions, clinicians would need to account for factors that could distort the value.

Even so, the findings add to a growing body of evidence that routine laboratory values can serve as unexpected windows into stroke severity. Previous studies have linked bilirubin levels to the severity of atherosclerosis, the buildup of plaque in arteries that underlies many strokes, and to the intensity of the inflammatory response that follows. The new study extends this work by showing that a derived ratio combining two routine values may capture the clinical picture even better than either value alone.

The researchers suggest that future studies should track patients after discharge, replicate the findings in larger populations, and explore whether the ratio could guide treatment decisions in real time. If the results hold up, a value calculated from a routine blood test could eventually become part of the standard clinical picture for acute stroke, helping clinicians answer one of the most urgent questions in medicine: how bad is this going to be?

Subject of Research: Admission direct bilirubin and direct bilirubin-to-lymphocyte ratio as exploratory markers of early severity and in-hospital functional status in acute ischemic stroke

Article Title: Admission direct bilirubin and direct bilirubin-to-lymphocyte ratio as exploratory markers of early severity and in-hospital functional status in acute ischemic stroke

Article References: Li, Y., Zhang, R., Luo, Y., & Gu, Y. (2026). Admission direct bilirubin and direct bilirubin-to-lymphocyte ratio as exploratory markers of early severity and in-hospital functional status in acute ischemic stroke. Frontiers in Stroke, 5, Article 1800285. https://doi.org/10.3389/fstro.2026.1800285

Image Credits: AI Generated

DOI: 10.3389/fstro.2026.1800285

Keywords: Admission, direct, bilirubin, bilirubin-to-lymphocyte, ratio, exploratory, markers, early, severity, in-hospital, functional, status